Rakiya Adediji
Gerontology · Montgomery, ALNPI 1720599772
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.0% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $386 and has fallen 60.0% since, to $154 in 2025.
Across 51 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$210
- Lilly USA, LLC$184
- Astellas Pharma US Inc$156
- AstraZeneca$98
- Novo Nordisk$87
- Pfizer$83
- plus $233 from 9 others
What the payments were for
- Food & beverage$95691%
- Education$959%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 7 | $210 |
| Lilly USA, LLC | 12 | $184 |
| Astellas Pharma US Inc | 5 | $156 |
| AstraZeneca | 5 | $98 |
| Novo Nordisk | 5 | $87 |
| Pfizer | 4 | $83 |
| Boehringer Ingelheim | 3 | $50 |
| Xeris Pharmaceuticals, Inc. | 2 | $45 |
| Amgen | 2 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $25 |
| Tonix Medicines, Inc. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Viatris Specialty LLC | 1 | $17 |
| Merck | 1 | $16 |
| Mylan Specialty L.p. | 1 | $13 |
How this compares
$1,051 in reported general payments places this provider in the 65th percentile of 143 gerontology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 103 | $101,634 |
| JardianceEmpagliflozin | 42 | $61,680 |
| TrulicityDulaglutide | 43 | $55,589 |
| JanuviaSitagliptin Phosphate | 26 | $30,271 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $26,191 |
| FarxigaDapagliflozin Propanediol | 24 | $25,680 |
| LinzessLinaclotide | 20 | $21,573 |
| MyrbetriqMirabegron | 13 | $11,761 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $5,473 |
| Atorvastatin Calcium | 379 | $3,959 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 168 | $3,278 |
| Duloxetine Hcl | 89 | $3,262 |
| Azelastine Hcl | 66 | $2,936 |
| Tizanidine Hcl | 125 | $2,692 |
| Levocetirizine Dihydrochloride | 216 | $2,328 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $87 | $101,634103 claims |
| Boehringer IngelheimJardiance | $50 | $61,68042 claims |
| Lilly USA, LLCTrulicity | $184 | $55,58943 claims |
| MerckJanuvia | $16 | $30,27126 claims |
| GSKTrelegy Ellipta | $210 | $26,19132 claims |
| AstraZenecaFarxiga | $98 | $25,68024 claims |
| Astellas Pharma US IncMyrbetriq | $156 | $11,76113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 143 gerontology providers in Alabama.
Other gerontology in Montgomery
- Ryan ShannonMontgomery$66K
- Sari CapiloutoMontgomery$9K
- Kristen OsborneMontgomery$5K
- Jawaneka EllersonMontgomery$2K
- Ashley PowellMontgomery$2K
- Sharon ReynoldsMontgomery$2K
- Bradley HammMontgomery$1K
- Heather CulliganMontgomery$889
- Claire BruceHuntsville$12K
- Michelle SanfordMobile$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.